[go: up one dir, main page]

AR076067A1 - Composiciones y metodos para modular la senda de senalizacion de wnt - Google Patents

Composiciones y metodos para modular la senda de senalizacion de wnt

Info

Publication number
AR076067A1
AR076067A1 ARP100100593A ARP100100593A AR076067A1 AR 076067 A1 AR076067 A1 AR 076067A1 AR P100100593 A ARP100100593 A AR P100100593A AR P100100593 A ARP100100593 A AR P100100593A AR 076067 A1 AR076067 A1 AR 076067A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
halogen
optionally substituted
alkoxy
alkyl
Prior art date
Application number
ARP100100593A
Other languages
English (en)
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42112245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076067(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of AR076067A1 publication Critical patent/AR076067A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Reivindicacion 1: Un compuesto que tiene la formula (1) o (2): o una sal fisiologicamente aceptable del mismo, en donde: el anillo E es un arilo o heteroarilo opcionalmente sustituido; A1 y A2 son independientemente un heterociclo de 1 a 5 átomos de carbono, quinolinilo, o un heteroarilo seleccionado a partir del grupo: (3) en donde cualquier heterociclo de A1 y A2 puede estar opcionalmente sustituido con -LC(O)R10; B es benzotiazolilo, quinolinilo o isoquinolinilo, cada uno de los cuales está opcionalmente sustituido con 1 a 3 grupos R6; X1, X2, X3 y X4 son independientemente CR7 o N; Y es fenilo o un heteroarilo de 5 a 6 miembros que contiene de 1 a 2 heteroátomos seleccionados a partir de N, O y S; Z es arilo, heterociclo de 1 a 5 átomos de carbono, o un heteroarilo de 5 a 6 miembros que contiene de 1 a 2 heteroátomos seleccionados a partir de N, O y S; cada Y y Z está opcionalmente sustituido con 1 a 3 grupos R6; R1 y R5 son independientemente H o alquilo de 1 a 6 átomos de carbono; R2 y R3 son independientemente H, alquilo de 1 a 6 átomos de carbono, o halogeno; R4 es halogeno, ciano, alcoxilo de 1 a 6 átomos de carbono, o un alquilo de 1 a 6 átomos de carbono opcionalmente sustituido con halogeno, alcoxilo o amino; R6 es hidrogeno, halogeno, alcoxilo de 1 a 6 átomos de carbono, -S(O)2R10, -C(O)OR10, -C(O)R10, -C(O)NR8R9, alquilo de 1 a 6 átomos de carbono, alquenilo de 2 a 6 átomos de carbono, o alquinilo de 2 a 6 átomos de carbono, cada uno de los cuales puede estar opcionalmente sustituido con halogeno, amino, hidroxilo, alcoxilo o ciano; halogeno, CN, -L-W, NR8R9, -L-C(O)R10, -L-C(O)OR10, -LC(O)NR8R9, OR10; -L-S(O)2R10 o -L-S(O)2NR8R9; R7 es H, halogeno, alcoxilo de 1 a 6 átomos de carbono, -L-S(O)2R10, alquilo de 1 a 6 átomos de carbono opcionalmente sustituido con halogeno, mino, hidroxilo, alcoxilo o ciano; NR8R9, -L-C(O)R10, -L-C(O)NR8R9, OR10 -L-S(O)2R10 o -L-S(O)2NR8R9; R8 y R9 son independientemente H, -L-W, o alquilo de 1 a 6 átomos de carbono, alquenilo de 2 a 6 átomos de carbono, o alquinilo de 2 a 6 átomos de carbono, cada uno de los cuales puede estar opcionalmente sustituido con halogeno, amino, hidroxilo, alcoxilo o ciano; o R8 y R9, junto con los átomos con los que están unidos, pueden formar un anillo; R10 es H, -L-W, o alquilo de 1 a 6 átomos de carbono, alquenilo de 2 a 6 átomos de carbono, o alquinilo de 2 a 6 átomos de carbono, cada uno de los cuales puede estar opcionalmente sustituido con halogeno, amino, hidroxilo, alcoxilo o ciano; L es un enlace o (CR2)1-4 en donde R es H o alquilo de 1 a 6 átomos de carbono; W es cicloalquilo de 3 a 7 átomos de carbono, heterociclo de 1 a 5 átomos de carbono, arilo o heteroarilo; m es de 0 a 4; n es de 0 a 3; y p es de 0 a 2.
ARP100100593A 2009-03-02 2010-03-01 Composiciones y metodos para modular la senda de senalizacion de wnt AR076067A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15659909P 2009-03-02 2009-03-02
US24518709P 2009-09-23 2009-09-23

Publications (1)

Publication Number Publication Date
AR076067A1 true AR076067A1 (es) 2011-05-18

Family

ID=42112245

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100593A AR076067A1 (es) 2009-03-02 2010-03-01 Composiciones y metodos para modular la senda de senalizacion de wnt

Country Status (40)

Country Link
US (4) US8546396B2 (es)
EP (2) EP2623493B1 (es)
JP (2) JP5490153B2 (es)
KR (1) KR101359873B1 (es)
CN (2) CN102731379B (es)
AR (1) AR076067A1 (es)
AU (1) AU2010221493C1 (es)
BR (1) BRPI1009235B8 (es)
CA (1) CA2753552C (es)
CL (1) CL2011002116A1 (es)
CO (1) CO6450669A2 (es)
CR (2) CR20190039A (es)
CU (1) CU24050B1 (es)
DK (1) DK2403832T3 (es)
DO (1) DOP2011000273A (es)
EA (1) EA021225B1 (es)
EC (1) ECSP11011359A (es)
ES (2) ES2543320T3 (es)
GE (2) GEP20146033B (es)
HN (1) HN2011002346A (es)
HR (1) HRP20140156T1 (es)
IL (1) IL214516A (es)
JO (1) JO2933B1 (es)
MA (1) MA33157B1 (es)
MX (1) MX2011009246A (es)
MY (1) MY150583A (es)
NI (1) NI201100165A (es)
NZ (2) NZ603137A (es)
PE (1) PE20120650A1 (es)
PL (1) PL2403832T3 (es)
PT (1) PT2403832E (es)
SG (1) SG173467A1 (es)
SI (1) SI2403832T1 (es)
SM (1) SMT201400032B (es)
TN (1) TN2011000378A1 (es)
TW (2) TWI429644B (es)
UA (1) UA103918C2 (es)
UY (2) UY32469A (es)
WO (1) WO2010101849A1 (es)
ZA (1) ZA201106750B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
CA2756535A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
CA2789189A1 (en) 2010-03-10 2011-09-15 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
PT3311666T (pt) 2010-08-18 2021-06-21 Biosplice Therapeutics Inc Dicetonas e hidroxicetonas como ativadores da via de sinalização de catenina
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
RU2017120287A (ru) * 2012-02-28 2018-11-15 АйАрЭм ЭлЭлСи ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43
US9725427B2 (en) * 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
US9234176B2 (en) * 2012-11-13 2016-01-12 The Board Of Trustees Of The Leland Stanford Junior University Chemically defined production of cardiomyocytes from pluripotent stem cells
KR101418168B1 (ko) * 2012-11-21 2014-07-09 부경대학교 산학협력단 신규 테트라하이드로피리디놀 유도체 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약제학적 조성물
SG10201606032VA (en) 2013-02-22 2016-09-29 Samumed Llc Gamma-Diketones As Wnt/Beta -Catenin Signaling Pathway Activators
CN103113353B (zh) * 2013-03-13 2014-09-10 中国科学院昆明植物研究所 三氮唑类化合物，其药物组合物和其制备方法与应用
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與ｗｎｔ抑制劑相關之標記
CA2905830C (en) 2013-03-12 2022-01-18 Curegenix Inc. Quinazoline and naphthyridine derivatives useful in the treatment of cancer
GB2513403A (en) * 2013-04-26 2014-10-29 Agency Science Tech & Res WNT pathway modulators
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
CN105492444B (zh) 2013-07-02 2018-09-07 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
CN105518005B (zh) 2013-07-02 2018-07-20 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
EP3039021A1 (en) 2013-08-30 2016-07-06 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
KR20160147800A (ko) * 2014-05-06 2016-12-23 에프. 호프만-라 로슈 아게 다능성 줄기세포의 심근세포로의 분화 방법
CN107106549B (zh) 2014-08-20 2020-06-16 萨穆梅德有限公司 用于治疗和预防老化皮肤和皱纹的γ–二酮
US9765299B2 (en) 2014-09-10 2017-09-19 Wisconsin Alumni Research Foundation Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
ES2922580T3 (es) * 2014-10-08 2022-09-16 Redx Pharma Plc Derivados de N-piridinilacetamida como inhibidores de la ruta de señalización WNT
DK3204378T6 (da) 2014-10-08 2022-07-18 Redx Pharma Plc N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
CA2976972A1 (en) * 2015-02-20 2016-08-25 Bayer Pharma Aktiengesellschaft 1,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitorsof the wnt signalling pathway
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
CN104876912B (zh) * 2015-04-08 2017-07-21 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
US20180112273A1 (en) * 2015-05-26 2018-04-26 Curegenix Corporation Tumor biomarkers and use thereof
US20180153884A1 (en) * 2015-05-31 2018-06-07 Curegenix Corporation Combination compositions for immunotherapy
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
EP3315499B1 (en) 2015-06-23 2021-04-07 Eisai R&D Management Co., Ltd. Crystal of (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US10624949B1 (en) 2015-07-27 2020-04-21 National Technology & Engineering Solutions Of Sandia, Llc Methods for treating diseases related to the wnt pathway
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
PL3344758T3 (pl) 2015-09-01 2022-01-03 Ncardia B.V. Sposób in vitro różnicowania populacji ludzkich pluripotentnych komórek macierzystych w populację komórek kardiomiocytów
CN107759584B (zh) * 2016-08-16 2021-06-01 苏州云轩医药科技有限公司 一种具有Wnt信号通路抑制活性的氨基五元杂环化合物及其应用
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
CN106749259B (zh) * 2015-11-19 2019-02-01 华东师范大学 一种环戊基嘧啶并吡咯类化合物的合成方法
CN107056755B (zh) * 2015-12-07 2019-02-22 苏州信诺维医药科技有限公司 五元杂环酰胺类wnt通路抑制剂
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
US20200306244A1 (en) 2016-06-22 2020-10-01 Novartis Ag Wnt inhibitors for use in the treatment of fibrosis
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
CN117752784A (zh) 2017-02-14 2024-03-26 诺华股份有限公司 Wnt抑制剂和抗PD-1抗体分子组合的给药方案
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
CN107441045B (zh) 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
CN108586452A (zh) * 2018-01-12 2018-09-28 重庆市碚圣医药科技股份有限公司 一种帕博西尼中间体的合成方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2019157085A2 (en) * 2018-02-06 2019-08-15 Vanderbilt University INHIBITION OF WNT/β-CATENIN SIGNALING IN THE TREATMENT OF OSTEOARTHRITIS
AU2018413791B2 (en) * 2018-03-23 2023-05-18 Step Pharma S.A.S. Aminopyrimidine derivatives as CTPS1 inhibitors
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US12281180B2 (en) 2018-07-13 2025-04-22 New York University Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
WO2020125759A1 (zh) * 2018-12-21 2020-06-25 汇瀚医疗科技有限公司 作为wnt信号通路抑制剂的化合物及其医学应用
CN111349093B (zh) * 2018-12-21 2021-07-02 汇瀚医疗科技有限公司 5,6-双环化合物作为wnt信号通路抑制剂及其医学应用
US11369609B2 (en) * 2019-05-02 2022-06-28 Yale University Small molecule Wnt inhibitor as treatment for dyslipidemia
CN114072408B (zh) * 2019-07-08 2023-05-12 南京明德新药研发有限公司 作为porcupine抑制剂的化合物及其应用
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021164742A1 (zh) * 2020-02-20 2021-08-26 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
IT202000019897A1 (it) * 2020-08-10 2022-02-10 Olon Spa Procedimento per la preparazione di un intermedio chiave del siponimod
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V Antibody fragment against fap
CN112472701B (zh) * 2020-12-04 2021-08-31 复旦大学附属中山医院 Wnt抑制剂Wnt-C59在制备治疗SCN5A突变致扩张型心肌病的药物中的应用
WO2023072263A1 (zh) * 2021-10-29 2023-05-04 南京明德新药研发有限公司 5-取代的吡啶-2(1h)-酮类化合物及其应用
KR102416464B1 (ko) * 2021-11-24 2022-07-05 중앙대학교 산학협력단 Lgk974를 포함하는 염증성 신장질환 예방 또는 치료용 조성물
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
WO2023213211A1 (zh) * 2022-05-06 2023-11-09 长沙晶易医药科技股份有限公司 2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用
WO2024009232A1 (en) * 2022-07-05 2024-01-11 Aurigene Oncology Limited Substituted n-(pyridin-2-yl)acetamide derivatives as cdk12/13 inhibitors
CN115784839B (zh) * 2022-11-11 2024-06-21 浙江工业大学 一种4-环己基-3-(三氟甲基)苯甲醇的制备方法
CN118496159B (zh) * 2024-07-18 2024-09-24 广州医科大学附属市八医院 一种化合物在制备具有预防和/或治疗肝纤维化作用的药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
CA2742411A1 (en) 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
TWI335221B (en) * 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US6762185B1 (en) * 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
US8030336B2 (en) * 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
EP1575952B1 (en) 2002-12-18 2009-02-18 Mallinckrodt Inc. Synthesis of heteroaryl acetamides
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US7652043B2 (en) * 2004-09-29 2010-01-26 The Johns Hopkins University WNT pathway antagonists
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
WO2006116503A2 (en) 2005-04-26 2006-11-02 Irm Llc Methods and compositions for modulating wnt signaling pathway
EA200970447A1 (ru) 2006-11-03 2009-10-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
EP1932830A1 (en) * 2006-12-11 2008-06-18 The Genetics Company, Inc. Sulfonamides and their use as a medicament
WO2008137408A1 (en) * 2007-04-30 2008-11-13 Genentech, Inc. Pyrazole inhibitors of wnt signaling
EP2003119A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Substituierte Acetamide als Modulatoren des EP2-Rezeptors
CN101896461A (zh) * 2007-12-13 2010-11-24 安姆根有限公司 γ分泌酶调节剂
JP2012517439A (ja) * 2009-02-06 2012-08-02 エラン ファーマシューティカルズ，インコーポレイテッド Ｊｕｎｎ−末端キナーゼの阻害薬
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt

Also Published As

Publication number Publication date
TW201329070A (zh) 2013-07-16
UY32469A (es) 2010-09-30
MX2011009246A (es) 2012-09-28
EP2403832B1 (en) 2013-11-20
US20110237573A1 (en) 2011-09-29
NI201100165A (es) 2012-02-02
CA2753552A1 (en) 2010-09-10
ZA201106750B (en) 2013-02-27
GEP20146082B (en) 2014-04-25
BRPI1009235A8 (pt) 2018-01-02
KR101359873B1 (ko) 2014-02-06
JO2933B1 (en) 2015-09-15
US20160082014A1 (en) 2016-03-24
CA2753552C (en) 2014-04-29
CR20110520A (es) 2012-03-26
BRPI1009235B1 (pt) 2020-07-14
JP5490153B2 (ja) 2014-05-14
CL2011002116A1 (es) 2012-01-27
ES2543320T3 (es) 2015-08-18
CN102731379A (zh) 2012-10-17
JP2012519210A (ja) 2012-08-23
EP2403832A1 (en) 2012-01-11
NZ603137A (en) 2013-02-22
CU20110165A7 (es) 2012-02-15
PT2403832E (pt) 2014-01-23
MY150583A (en) 2014-01-30
AU2010221493A1 (en) 2011-10-13
EP2623493A1 (en) 2013-08-07
EA021225B1 (ru) 2015-05-29
TWI429644B (zh) 2014-03-11
TN2011000378A1 (en) 2013-03-27
GEP20146033B (en) 2014-02-10
SG173467A1 (en) 2011-09-29
SMT201400032B (it) 2014-07-07
US20180000832A1 (en) 2018-01-04
US10251893B2 (en) 2019-04-09
CU24050B1 (es) 2014-12-26
CO6450669A2 (es) 2012-05-31
EA201101244A1 (ru) 2012-04-30
BRPI1009235A (pt) 2017-08-22
DOP2011000273A (es) 2012-01-31
CN102369187B (zh) 2014-06-04
HN2011002346A (es) 2015-03-23
UA103918C2 (en) 2013-12-10
US20130310375A1 (en) 2013-11-21
JP2014129381A (ja) 2014-07-10
WO2010101849A1 (en) 2010-09-10
ES2445526T3 (es) 2014-03-03
PE20120650A1 (es) 2012-06-03
BRPI1009235B8 (pt) 2021-05-25
MA33157B1 (fr) 2012-03-01
CN102731379B (zh) 2015-05-06
IL214516A (en) 2016-10-31
US9238646B2 (en) 2016-01-19
SI2403832T1 (sl) 2014-03-31
CN102369187A (zh) 2012-03-07
PL2403832T3 (pl) 2014-04-30
AU2010221493C1 (en) 2013-11-07
NZ595339A (en) 2012-11-30
KR20110122870A (ko) 2011-11-11
EP2623493B1 (en) 2015-04-22
UY39128A (es) 2021-04-30
TW201043622A (en) 2010-12-16
IL214516A0 (en) 2011-09-27
ECSP11011359A (es) 2011-11-30
CR20190039A (es) 2019-04-02
US8546396B2 (en) 2013-10-01
AU2010221493B2 (en) 2012-06-07
HRP20140156T1 (hr) 2014-03-14
HK1160464A1 (en) 2012-08-17
DK2403832T3 (da) 2014-01-06

Similar Documents

Publication Publication Date Title
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
DOP2011000061A (es) Compuestos de pirrol
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR044629A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
ECSP11011318A (es) Derivados de benzofurano
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
AR075510A1 (es) Inhibidores del virus de la hepatitis c
CO6251263A2 (es) Derivados de bencimidazol e indol sustutuidos por oxadiazol y oxazol como inhibidores de dgat1
AR079634A1 (es) Inhibidores del virus de la hepatitis c
NI201000150A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización.
CO6300865A2 (es) Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica
PE20130647A1 (es) Indoles
AR066014A1 (es) Difenil- dihidro -imidazopiridinonas. composiciones farmaceuticas y usos.
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
AR082619A1 (es) Inhibidores del virus de la hepatitis c
AR065249A1 (es) Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales.
AR052419A1 (es) Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit
AR066531A1 (es) Dihidroquinonas y dihidronaftiridinas como inhibidores de las jnk, composicion farmaceutica
CO6150147A2 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii

Legal Events

Date Code Title Description
FG Grant, registration